Royalty Pharma plc (RPRX) FY2024 Q1 P&L / Income Statement

Royalty Pharma plc (RPRX) FY2024 Q1 P&L / Income Statement

Income statement for 2024-01-01 through 2024-03-31. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Revenues

567,978,000 US dollars

Total operating expenses, net

641,752,000 US dollars

Operating (loss)/income

negative 73,774,000 US dollars

Total other income, net

69,501,000 US dollars

Consolidated net (loss)/income before tax

negative 4,273,000 US dollars

Income tax expense

0 US dollars

Consolidated net (loss)/income

negative 4,273,000 US dollars

Financial Royalty Assets

541,546,000 US dollars

Other Royalty Income

26,432,000 US dollars

Research and development funding expense

500,000 US dollars

Provision for changes in expected cash flows from financial royalty assets

583,600,000 US dollars

General and administrative expenses

57,652,000 US dollars

Chart connections

• Revenue minus operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
• Of which attributable to Royalty Pharma plc: $4.78 M; to noncontrolling interests: −$9.05 M.